{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:14:22Z","timestamp":1784297662037,"version":"3.55.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004203","name":"Ontario Institute for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004203","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s11307-025-02013-4","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T11:34:14Z","timestamp":1747913654000},"page":"606-616","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeted Radionuclide Therapy Using a Lutetium-177 Labeled Human Anti-CD133 Antibody"],"prefix":"10.1007","volume":"27","author":[{"given":"Kevin","family":"Wyszatko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Janzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Napoleon","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teesha","family":"Komal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek M.","family":"Kwiecien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila K.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saman","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"2013_CR1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.radonc.2013.06.003","volume":"108","author":"C Peitzsch","year":"2013","unstructured":"Peitzsch C, Kurth I, Kunz-Schughart L et al (2013) Discovery of the cancer stem cell related determinants of radioresistance. Radiother Oncol 108:378\u2013387. https:\/\/doi.org\/10.1016\/j.radonc.2013.06.003","journal-title":"Radiother Oncol"},{"key":"2013_CR2","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1476-4598-5-67","volume":"5","author":"G Liu","year":"2006","unstructured":"Liu G, Yuan X, Zeng Z et al (2006) Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67. https:\/\/doi.org\/10.1186\/1476-4598-5-67","journal-title":"Mol Cancer"},{"key":"2013_CR3","doi-asserted-by":"publisher","first-page":"8205","DOI":"10.1158\/1078-0432.CCR-08-0644","volume":"14","author":"R Pallini","year":"2008","unstructured":"Pallini R, Ricci-Vitiani L, Banna GL et al (2008) Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res 14:8205\u20138212. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0644","journal-title":"Clin Cancer Res"},{"key":"2013_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/7512632","volume":"2019","author":"F Brugnoli","year":"2019","unstructured":"Brugnoli F, Grassilli S, Al-Qassab Y et al (2019) CD133 in breast cancer cells: more than a stem cell marker. J Oncol 2019:1\u20138. https:\/\/doi.org\/10.1155\/2019\/7512632","journal-title":"J Oncol"},{"key":"2013_CR5","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.bbrc.2006.10.128","volume":"351","author":"A Suetsugu","year":"2006","unstructured":"Suetsugu A, Nagaki M, Aoki H et al (2006) Characterization of CD133+ hepatocellular carcinoma cells as cancer stem\/progenitor cells. Biochem Biophys Res Commun 351:820\u2013824. https:\/\/doi.org\/10.1016\/j.bbrc.2006.10.128","journal-title":"Biochem Biophys Res Commun"},{"key":"2013_CR6","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1038\/sj.bjc.6605626","volume":"102","author":"L Hu","year":"2010","unstructured":"Hu L, McArthur C, Jaffe RB (2010) Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer 102:1276\u20131283. https:\/\/doi.org\/10.1038\/sj.bjc.6605626","journal-title":"Br J Cancer"},{"key":"2013_CR7","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s12253-016-0169-z","volume":"23","author":"E Kalantari","year":"2017","unstructured":"Kalantari E, Asgari M, Nikpanah S et al (2017) Co-expression of putative cancer stem cell markers CD44 and CD133 in prostate carcinomas. Pathol Oncol Res 23:793\u2013802. https:\/\/doi.org\/10.1007\/s12253-016-0169-z","journal-title":"Pathol Oncol Res"},{"key":"2013_CR8","first-page":"5821","volume":"63","author":"SK Singh","year":"2003","unstructured":"Singh SK, Clarke ID, Terasaki M et al (2003) Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821\u20135828","journal-title":"Cancer Res"},{"key":"2013_CR9","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","volume":"344","author":"AP Patel","year":"2014","unstructured":"Patel AP, Tirosh I, Trombetta JJ et al (2014) Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science 344:1396\u20131401. https:\/\/doi.org\/10.1126\/science.1254257","journal-title":"Science"},{"key":"2013_CR10","doi-asserted-by":"publisher","first-page":"16281","DOI":"10.1073\/pnas.0905653106","volume":"106","author":"G Bertolini","year":"2009","unstructured":"Bertolini G, Roz L, Perego P et al (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 106:16281\u201316286. https:\/\/doi.org\/10.1073\/pnas.0905653106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2013_CR11","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1038\/sj.leu.2402255","volume":"15","author":"M Bhatia","year":"2001","unstructured":"Bhatia M (2001) AC133 expression in human stem cells. Leukemia 15:1685\u20131688. https:\/\/doi.org\/10.1038\/sj.leu.2402255","journal-title":"Leukemia"},{"key":"2013_CR12","doi-asserted-by":"publisher","unstructured":"Stratford EW, Bostad M, Castro R, et al (2013) Photochemical internalization of CD133-targeting immunotoxins efficiently depletes sarcoma cells with stem-like properties and reduces tumorigenicity. Biochimica et Biophysica Acta (BBA) - General Subjects 1830:4235\u20134243. https:\/\/doi.org\/10.1016\/j.bbagen.2013.04.033","DOI":"10.1016\/j.bbagen.2013.04.033"},{"key":"2013_CR13","doi-asserted-by":"publisher","unstructured":"Sarrett SM, Rodriguez C, Delaney S, Hosny MM, Sebastiano J, Santos-Coquillat A, Keina\u0308nen OM, Carter LM, Lastwika KJ, Lampe PD, Zeglis BM. Evaluating CD133 as a radiotheranostic target in small-cell lung cancer. Molecular Pharmaceutics. 2024 Feb 8;21(3):1402-13. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.3c01063","DOI":"10.1021\/acs.molpharmaceut.3c01063"},{"key":"2013_CR14","doi-asserted-by":"publisher","unstructured":"Dinghu W, Xueyan J, Saimei Q, et al (2017) Radioimmunotherapy for CD133(+) colonic cancer stem cells inhibits tumor development in nude mice. Oncotarget 8:44004\u201344014. https:\/\/doi.org\/10.18632\/oncotarget.16868","DOI":"10.18632\/oncotarget.16868"},{"key":"2013_CR15","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s13346-012-0066-2","volume":"3","author":"JR Ohlfest","year":"2013","unstructured":"Ohlfest JR, Zellmer DM, Panyam J et al (2013) Immunotoxin targeting CD133(+) breast carcinoma cells. Drug Deliv Transl Res 3:195\u2013204. https:\/\/doi.org\/10.1007\/s13346-012-0066-2","journal-title":"Drug Deliv Transl Res"},{"key":"2013_CR16","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1038\/s41375-019-0418-8","volume":"33","author":"C Bueno","year":"2019","unstructured":"Bueno C, Velasco-Hernandez T, Guti\u00e9rrez-Ag\u00fcera F et al (2019) CD133-directed CAR T-cells for MLL leukemia: on-target, off-tumor myeloablative toxicity. Leukemia 33:2090\u20132125. https:\/\/doi.org\/10.1038\/s41375-019-0418-8","journal-title":"Leukemia"},{"key":"2013_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF02789485","volume":"21","author":"J-E Fr\u00f6din","year":"1992","unstructured":"Fr\u00f6din J-E, Lefvert A-K, Mellstedt H (1992) The clinical significance of HAMA in patients treated with mouse monoclonal antibodies. Cell Biophys 21:153\u2013165. https:\/\/doi.org\/10.1007\/BF02789485","journal-title":"Cell Biophys"},{"key":"2013_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000084184","volume":"26","author":"NR Gonzales","year":"2005","unstructured":"Gonzales NR, Pascalis RD, Schlom J, Kashmiri SVS (2005) Minimizing the immunogenicity of antibodies for clinical application. TBI 26:31\u201343. https:\/\/doi.org\/10.1159\/000084184","journal-title":"TBI"},{"key":"2013_CR19","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","volume":"2","author":"FA Harding","year":"2010","unstructured":"Harding FA, Stickler MM, Razo J, DuBridge RB (2010) The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2:256\u2013265. https:\/\/doi.org\/10.4161\/mabs.2.3.11641","journal-title":"MAbs"},{"key":"2013_CR20","unstructured":"Williams R (2013) Generation of anti-CD133 human synthetic antibodies as tools for exploring CD133 function. Thesis,\u00a0University of Toronto.\u00a0https:\/\/utoronto.scholaris.ca\/items\/629b4137-29af-40ba-94ea-f2724ab07ec1"},{"key":"2013_CR21","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.stem.2020.04.008","volume":"26","author":"P Vora","year":"2020","unstructured":"Vora P, Venugopal C, Salim SK et al (2020) The rational development of CD133-targeting immunotherapies for glioblastoma. Cell Stem Cell 26:832-844.e6. https:\/\/doi.org\/10.1016\/j.stem.2020.04.008","journal-title":"Cell Stem Cell"},{"issue":"114","key":"2013_CR22","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/S0969-8051(22)02137-0","volume":"1","author":"K Wyszatko","year":"2022","unstructured":"Wyszatko K, Silva LR, Komal T, Kwon LY, Ventura M, Singh S, Valliant J, Sadeghi S (2022) Preclinical development of CD133 targeted immunoPET probes. Nuclear Medic Biol 1(114):S19-20","journal-title":"Nuclear Medic Biol"},{"key":"2013_CR23","doi-asserted-by":"publisher","first-page":"B079","DOI":"10.1158\/2326-6066.IMM2016-B079","volume":"4","author":"P Vora","year":"2016","unstructured":"Vora P, Chokshi C, Qazi M et al (2016) Abstract B079: The efficacy of CD133 BiTEs and CAR-T cells in preclinical model of recurrent glioblastoma. Cancer Immunol Res 4:B079\u2013B079. https:\/\/doi.org\/10.1158\/2326-6066.IMM2016-B079","journal-title":"Cancer Immunol Res"},{"key":"2013_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-5894-4","volume-title":"Prominin-1 (CD133): New insights on stem & cancer stem cell biology","author":"D Corbeil","year":"2013","unstructured":"Corbeil D (2013) Prominin-1 (CD133): New insights on stem & cancer stem cell biology. Springer, New York, New York, NY"},{"key":"2013_CR25","doi-asserted-by":"publisher","first-page":"101467","DOI":"10.1016\/j.eucr.2020.101467","volume":"34","author":"P Bilinski","year":"2020","unstructured":"Bilinski P, Webb M (2020) An exceptional response to 177LuPSMA undermined by neuroendocrine transformation. Urol Case Rep 34:101467. https:\/\/doi.org\/10.1016\/j.eucr.2020.101467","journal-title":"Urol Case Rep"},{"key":"2013_CR26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1038\/pcan.2017.23","volume":"20","author":"RJS Calopedos","year":"2017","unstructured":"Calopedos RJS, Chalasani V, Asher R et al (2017) Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis 20:352\u2013360. https:\/\/doi.org\/10.1038\/pcan.2017.23","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2013_CR27","doi-asserted-by":"publisher","unstructured":"Weng D, Jin X, Qin S, Lan X, Chen C, Sun X, She X, Dong C, An R. Radioimmunotherapy for CD133 (+) colonic cancer stem cells inhibits tumor development in nude mice. Oncotarget. 2017 Apr 6;8(27):44004. https:\/\/doi.org\/10.18632\/oncotarget.16868","DOI":"10.18632\/oncotarget.16868"},{"key":"2013_CR28","doi-asserted-by":"publisher","first-page":"6997","DOI":"10.2147\/IJN.S86592","volume":"10","author":"Y-W Chen","year":"2015","unstructured":"Chen Y-W, Liou G-G, Pan H-B et al (2015) Specific detection of CD133-positive tumor cells with iron oxide nanoparticles labeling using noninvasive molecular magnetic resonance imaging. Int J Nanomedicine 10:6997\u20137018. https:\/\/doi.org\/10.2147\/IJN.S86592","journal-title":"Int J Nanomedicine"},{"key":"2013_CR29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.nucmedbio.2021.03.006","volume":"96\u201397","author":"W Delbart","year":"2021","unstructured":"Delbart W, Ghanem GE, Karfis I et al (2021) Investigating intrinsic radiosensitivity biomarkers to peptide receptor radionuclide therapy with [177Lu]Lu-DOTATATE in a panel of cancer cell lines. Nucl Med Biol 96\u201397:68\u201379. https:\/\/doi.org\/10.1016\/j.nucmedbio.2021.03.006","journal-title":"Nucl Med Biol"},{"key":"2013_CR30","doi-asserted-by":"publisher","first-page":"187","DOI":"10.5625\/lar.2016.32.4.187","volume":"32","author":"JY Lee","year":"2016","unstructured":"Lee JY, Kim M-S, Kim EH et al (2016) Retrospective growth kinetics and radiosensitivity analysis of various human xenograft models. Lab Anim Res 32:187\u2013193. https:\/\/doi.org\/10.5625\/lar.2016.32.4.187","journal-title":"Lab Anim Res"},{"issue":"13","key":"2013_CR31","doi-asserted-by":"publisher","first-page":"22034","DOI":"10.18632\/oncotarget.15787","volume":"8","author":"A Maisonial-Besset","year":"2017","unstructured":"Maisonial-Besset A, Witkowski T, Navarro-Teulon I, Berthier-Vergnes O, Fois G, Zhu Y, Besse S, Bawa O, Briat A, Quintana M, Pichard A (2017) Tetraspanin 8 (TSPAN 8) as a potential target for radio-immunotherapy of colorectal cancer. Oncotarget. 8(13):22034","journal-title":"Oncotarget."},{"key":"2013_CR32","first-page":"600","volume":"53","author":"JW Greiner","year":"1993","unstructured":"Greiner JW, Ullmann CD, Nieroda C et al (1993) Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon. Cancer Res 53:600\u2013608","journal-title":"Cancer Res"},{"key":"2013_CR33","first-page":"2889","volume":"51","author":"J Schlom","year":"1991","unstructured":"Schlom J, Siler K, Milenic DE et al (1991) Monoclonal antibody-based therapy of a human tumor xenograft with a 177lutetium-labeled immunoconjugate. Cancer Res 51:2889\u20132896","journal-title":"Cancer Res"},{"key":"2013_CR34","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1021\/mp4005047","volume":"11","author":"Z Liu","year":"2014","unstructured":"Liu Z, Ma T, Liu H et al (2014) 177 Lu-labeled antibodies for EGFR-Targeted SPECT\/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model. Mol Pharmaceutics 11:800\u2013807. https:\/\/doi.org\/10.1021\/mp4005047","journal-title":"Mol Pharmaceutics"},{"key":"2013_CR35","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1002\/1522-2683(200205)23:9<1348::AID-ELPS1348>3.0.CO;2-V","volume":"23","author":"X Zhu","year":"2002","unstructured":"Zhu X, Lever SZ (2002) Formation kinetics and stability studies on the lanthanide complexes of 1,4,7,10-tetraazacyclododecane-N, N\u2019, N\u2019\u2019, N\u2019\u2019\u2019-tetraacetic acid by capillary electrophoresis. Electrophoresis 23:1348\u20131356. https:\/\/doi.org\/10.1002\/1522-2683(200205)23:9\/3c1348::AID-ELPS1348\/3e3.0.CO;2-V","journal-title":"Electrophoresis"},{"key":"2013_CR36","doi-asserted-by":"publisher","first-page":"E692","DOI":"10.1073\/pnas.1314189111","volume":"111","author":"S Gaedicke","year":"2014","unstructured":"Gaedicke S, Braun F, Prasad S et al (2014) Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells. PNAS 111:E692\u2013E701. https:\/\/doi.org\/10.1073\/pnas.1314189111","journal-title":"PNAS"},{"key":"2013_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/4906934","volume":"2022","author":"K-H Jung","year":"2022","unstructured":"Jung K-H, Lee JH, Kim M et al (2022) Celecoxib-induced modulation of colon cancer CD133 expression occurs through akt inhibition and is monitored by 89Zr immuno-PET. Mol Imaging 2022:1\u201312. https:\/\/doi.org\/10.1155\/2022\/4906934","journal-title":"Mol Imaging"},{"key":"2013_CR38","unstructured":"Liu Y, Jin X, Lan X, et al (2016) SPECT imaging of colorectal cancer by targeting CD133 receptor with 99mTc-labeled monoclonal antibody. Q J Nucl Med Mol Imaging"},{"key":"2013_CR39","doi-asserted-by":"publisher","first-page":"232","DOI":"10.2967\/jnumed.120.245837","volume":"62","author":"Y Funase","year":"2021","unstructured":"Funase Y, Nakamura E, Kajita M et al (2021) Preclinical characterization of the radioimmunoconjugate 111 in or 90 Y-FF-21101 against a P-cadherin\u2013expressing tumor in a mouse xenograft model and a nonhuman primate. J Nucl Med 62:232\u2013239. https:\/\/doi.org\/10.2967\/jnumed.120.245837","journal-title":"J Nucl Med"},{"key":"2013_CR40","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1158\/0008-5472.CAN-14-3477","volume":"75","author":"S Heskamp","year":"2015","unstructured":"Heskamp S, Hobo W, Molkenboer-Kuenen JDM et al (2015) Noninvasive Imaging of Tumor PD-L1 expression using radiolabeled Anti\u2013PD-L1 antibodies. Can Res 75:2928\u20132936. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3477","journal-title":"Can Res"},{"key":"2013_CR41","doi-asserted-by":"publisher","first-page":"899","DOI":"10.2967\/jnumed.119.225854","volume":"60","author":"RM Reilly","year":"2019","unstructured":"Reilly RM (2019) Immuno-PET to optimize the dose of monoclonal antibodies for cancer therapy: how much is enough? J Nucl Med 60:899\u2013901. https:\/\/doi.org\/10.2967\/jnumed.119.225854","journal-title":"J Nucl Med"},{"key":"2013_CR42","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1118\/1.3581059","volume":"38","author":"P Kletting","year":"2011","unstructured":"Kletting P, Kull T, Bunjes D et al (2011) Optimal preloading in radioimmunotherapy with anti-CD45 antibody: Optimal preloading in radioimmunotherapy with anti-CD45 antibody. Med Phys 38:2572\u20132578. https:\/\/doi.org\/10.1118\/1.3581059","journal-title":"Med Phys"},{"key":"2013_CR43","doi-asserted-by":"publisher","first-page":"5015","DOI":"10.1200\/JCO.2021.39.15_suppl.5015","volume":"39","author":"ST Tagawa","year":"2021","unstructured":"Tagawa ST, Sun M, Sartor AO et al (2021) Phase I study of 225 Ac-J591 for men with metastatic castration-resistant prostate cancer (mCRPC). JCO 39:5015\u20135015. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.5015","journal-title":"JCO"},{"key":"2013_CR44","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1002\/cncr.32072","volume":"125","author":"ST Tagawa","year":"2019","unstructured":"Tagawa ST, Vallabhajosula S, Christos PJ et al (2019) Phase 1\/2 study of fractionated dose lutetium-177\u2013labeled anti\u2013prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer. Cancer 125:2561\u20132569. https:\/\/doi.org\/10.1002\/cncr.32072","journal-title":"Cancer"},{"key":"2013_CR45","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"2013_CR46","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1002\/(sici)1097-0142(19971215)80:12+<2749::aid-cncr55>3.3.co;2-k","volume":"80","author":"ME Juweid","year":"1997","unstructured":"Juweid ME, Zhang CH, Blumenthal RD et al (1997) Factors influencing hematologic toxicity of radioimmunotherapy with 131I-labeled anti-carcinoembryonic antigen antibodies. Cancer 80:2749\u20132753. https:\/\/doi.org\/10.1002\/(sici)1097-0142(19971215)80:12+\/3c2749::aid-cncr55\/3e3.3.co;2-k","journal-title":"Cancer"},{"key":"2013_CR47","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.2967\/jnumed.110.079947","volume":"51","author":"S Baechler","year":"2010","unstructured":"Baechler S, Hobbs RF, Jacene HA et al (2010) Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90 Y-Ibritumomab Tiuxetan or 131 I-Tositumomab. J Nucl Med 51:1878\u20131884. https:\/\/doi.org\/10.2967\/jnumed.110.079947","journal-title":"J Nucl Med"},{"key":"2013_CR48","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1158\/0008-5472.CAN-06-2363","volume":"67","author":"M Persson","year":"2007","unstructured":"Persson M, Gedda L, Lundqvist H et al (2007) [177Lu]Pertuzumab: experimental therapy of HER-2\u2013expressing xenografts. Can Res 67:326\u2013331. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-2363","journal-title":"Can Res"},{"key":"2013_CR49","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1002\/pros.20856","volume":"69","author":"MP Kelly","year":"2009","unstructured":"Kelly MP, Lee ST, Lee F-T et al (2009) Therapeutic efficacy of 177Lu-CHX-A\u2033-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy. Prostate 69:92\u2013104. https:\/\/doi.org\/10.1002\/pros.20856","journal-title":"Prostate"},{"key":"2013_CR50","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1002\/cam4.562","volume":"5","author":"R Phaeton","year":"2016","unstructured":"Phaeton R, Jiang Z, Revskaya E et al (2016) Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer. Cancer Med 5:9\u201316. https:\/\/doi.org\/10.1002\/cam4.562","journal-title":"Cancer Med"},{"key":"2013_CR51","first-page":"327","volume":"45","author":"AH Brouwers","year":"2004","unstructured":"Brouwers AH, van Eerd JEM, Frielink C et al (2004) Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med 45:327\u2013337","journal-title":"J Nucl Med"},{"key":"2013_CR52","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s13148-021-01025-5","volume":"13","author":"H Li","year":"2021","unstructured":"Li H, Ma L, Bian X et al (2021) FK228 sensitizes radioresistant small cell lung cancer cells to radiation. Clin Epigenet 13:41. https:\/\/doi.org\/10.1186\/s13148-021-01025-5","journal-title":"Clin Epigenet"},{"key":"2013_CR53","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.2967\/jnumed.117.193359","volume":"58","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Stuparu AD, Evans-Axelsson S et al (2017) Establishing 177 Lu-PSMA-617 radioligand therapy in a syngeneic model of murine prostate cancer. J Nucl Med 58:1786\u20131792. https:\/\/doi.org\/10.2967\/jnumed.117.193359","journal-title":"J Nucl Med"},{"key":"2013_CR54","doi-asserted-by":"publisher","first-page":"592","DOI":"10.5966\/sctm.2012-0003","volume":"1","author":"MG Muraro","year":"2012","unstructured":"Muraro MG, Mele V, D\u00e4ster S et al (2012) CD133+, CD166+CD44+, and CD24+CD44+ phenotypes fail to reliably identify cell populations with cancer stem cell functional features in established human colorectal cancer cell lines. Stem Cells Transl Med 1:592\u2013603. https:\/\/doi.org\/10.5966\/sctm.2012-0003","journal-title":"Stem Cells Transl Med"},{"key":"2013_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010714","volume":"5","author":"TMA Elsaba","year":"2010","unstructured":"Elsaba TMA, Martinez-Pomares L, Robins AR et al (2010) The stem cell marker cd133 associates with enhanced colony formation and cell motility in colorectal cancer. PLoS ONE 5:e10714. https:\/\/doi.org\/10.1371\/journal.pone.0010714","journal-title":"PLoS ONE"},{"key":"2013_CR56","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3109\/02841868809090333","volume":"27","author":"HR Withers","year":"1988","unstructured":"Withers HR, Taylor JMG, Maciejewski B (1988) The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 27:131\u2013146. https:\/\/doi.org\/10.3109\/02841868809090333","journal-title":"Acta Oncol"},{"key":"2013_CR57","doi-asserted-by":"publisher","first-page":"7330","DOI":"10.1158\/1078-0432.CCR-08-0797","volume":"14","author":"A Veeravagu","year":"2008","unstructured":"Veeravagu A, Liu Z, Niu G et al (2008) Integrin \u03b1v\u03b23-targeted radioimmunotherapy of glioblastoma multiforme. Clin Cancer Res 14:7330\u20137339. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0797","journal-title":"Clin Cancer Res"},{"key":"2013_CR58","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10555-007-9056-0","volume":"26","author":"BJ Moeller","year":"2007","unstructured":"Moeller BJ, Richardson RA, Dewhirst MW (2007) Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 26:241\u2013248. https:\/\/doi.org\/10.1007\/s10555-007-9056-0","journal-title":"Cancer Metastasis Rev"},{"key":"2013_CR59","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/abt\/tby010","volume":"1","author":"AH Staudacher","year":"2018","unstructured":"Staudacher AH, Liapis V, Brown MP (2018) Therapeutic targeting of tumor hypoxia and necrosis with antibody \u03b1-radioconjugates. Antib Ther 1:55\u201363. https:\/\/doi.org\/10.1093\/abt\/tby010","journal-title":"Antib Ther"},{"key":"2013_CR60","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/sj.bjc.6690337","volume":"80","author":"SJ Kennel","year":"1999","unstructured":"Kennel SJ, Boll R, Stabin M et al (1999) Radioimmunotherapy of micrometastases in lung with vascular targeted213Bi. Br J Cancer 80:175\u2013184. https:\/\/doi.org\/10.1038\/sj.bjc.6690337","journal-title":"Br J Cancer"},{"key":"2013_CR61","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29369","author":"MR Alam","year":"2022","unstructured":"Alam MR, Singh SB, Thapaliya S et al (2022) A review of 177Lutetium-PSMA and 225Actinium-PSMA as emerging theranostic agents in prostate cancer. Cureus. https:\/\/doi.org\/10.7759\/cureus.29369","journal-title":"Cureus"},{"key":"2013_CR62","doi-asserted-by":"publisher","first-page":"e003289","DOI":"10.1136\/jitc-2021-003289","volume":"10","author":"M Seyfrid","year":"2022","unstructured":"Seyfrid M, Maich WT, Shaikh MV et al (2022) CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment. J Immunother Cancer 10:e003289. https:\/\/doi.org\/10.1136\/jitc-2021-003289","journal-title":"J Immunother Cancer"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02013-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-025-02013-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-02013-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T15:18:13Z","timestamp":1757171893000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-025-02013-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["2013"],"URL":"https:\/\/doi.org\/10.1007\/s11307-025-02013-4","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"assertion":[{"value":"19 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}